Adjusting transgene expression levels in lymphocytes with a set of inducible promoters

Journal of Gene Medicine

Volumn 12, Issue 6, 2010, Pages 501-515

  Danke, Christina ^a   Gr̈unz, Xandra ^a   Wittmann, Jürgen ^b   Schmidt, Andreas ^a   Agha Mohammadi, Siamak ^c   Kutsch, Olaf ^d   Jäck, Hans Martin ^b   Hillen, Wolfgang ^a   Berens, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Cell death; Doxycycline; Gene regulation; Inducible expression; Lymphocytes; Reporter genes

Indexed keywords

CASPASE 3; CD123 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; TETRACYCLINE; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; B LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE MAMMARY TUMOR ONCOVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; ANIMAL; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; JURKAT CELL LINE; METABOLISM; MOUSE; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; B-LYMPHOCYTES; CASPASE 3; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; JURKAT CELLS; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSGENES;

EID: 77954606202     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1461     Document Type: Article

References (53)

1. Berens C, Hillen W. Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur J Biochem2003; 270: 3109-3121.
2. Krueger C, Pfleiderer K, Hillen W, et al. Tetracycline derivatives: alternative effectors for Tet transregulators. BioTechniques 2004; 37: 546-550. (Pubitemid 39391168)
3. Saez E, No D, West A, et al. Inducible gene expression in mammalian cells and transgenic mice. Curr Opin Biotechnol 1997; 8: 608-616.
4. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
5. Ackland-Berglund CE, Leib DA. Efficacy of tetracycline-controlled gene expression is influenced by cell type. BioTechniques 1995; 18: 196-200.
6. Howe JR, Skryabin BV, Belcher SM, et al. The responsiveness of a tetracycline-sensitive expression system differs in different cell lines. J Biol Chem 1995; 270: 14168-14174.
7. Barde I, Zanta-Boussif MA, Paisant S, et al. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol Ther 2006; 13: 382-390.
8. Krueger C, Danke C, Pfleiderer K, et al. A gene regulation system with four distinct expression levels. J Gene Med 2006; 8: 1037-1047.
9. Rang A, Will H. The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 2000; 28: 1120-1125. (Pubitemid 30107680)
10. Knott A, Drueppel L, Beyer T, et al. An optimized conditional suicide switch using doxycycline-dependent expression of human tBid. Cancer Biol Ther 2005; 4: 532-536.
11. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-1093.
12. Sleat DE, El-Banna M, Sohar I, et al. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2008; 94: 222-233.
13. Rossi FMV, Guicherit OM, Spicher A, et al. Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet 1998; 20: 389-393.
14. Forster K, Helbl V, Lederer T, et al. Tetracycline-inducible expression systems with reduced basal activity in mammalian cells. Nucleic Acids Res 1999; 27: 708-710.
15. Freundlieb S, Schirra-M̈uller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999; 1: 4-12. (Pubitemid 129631058)
16. Clontech pTRE-Tight vectors. Clontechniques. Clontech: Palo Alto, CA, 2003.
17. Agha-Mohammadi S, O'Malley M, Etemad A, et al. Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 2004; 6: 817-828.
18. Marzio G, Verhoef K, Vink M, et al. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci USA 2001; 98: 6342-6347.
19. Hoffmann A, Villalba M, Journot L, et al. A novel tetracycline-dependent expression vector with low basal expression and potent regulatory properties in various mammalian cell lines. Nucleic Acids Res 1997; 25: 1078-1079.
20. Backman CM, Zhang Y, Hoffer BJ, et al. Tetracycline-inducible expression systems for the generation of transgenic animals: a comparison of various inducible systems carried in a single vector. J Neurosci Methods 2004; 139: 257-262.
21. Pluta K, Luce MJ, Bao L, et al. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005; 7: 803-817.
22. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 2009; 9: 195-205.
23. Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009; 228: 9-22.
24. Kaiko GE, Horvat JC, Beagley KW, et al. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008; 123: 326-338.
25. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009; 9: 15-27.
26. Osborne BA. Apoptosis and the maintenance of homoeostasis in the immune system. Curr Opin Immunol 1996; 8: 245-254. (Pubitemid 26166990)
27. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 2008; 8: 970-976.
28. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007; 15: 1248-1252.
29. de Witte MA, Jorritsma A, Swart E, et al. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 2008; 180: 6365-6373.
30. KiuruM, BoyerJL, O'ConnorTP, et al. Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 2009; 4: 289-300.
31. Geraldes P, Rebrovich M, Herrmann K, et al. Ig heavy chain promotes mature B cell survival in the absence of light chain. J Immunol 2007; 179: 1659-1668.
32. Huai J, Firat E, Niedermann G. Inducible gene expression with the Tet-on system in CD4+ T cells and thymocytes of mice. Genesis 2007; 45: 427-431.
33. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133: 250-264.
34. Alt F, Rosenberg N, Lewis S, et al. Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes. Cell 1981; 27: 381-390.
35. Lanier LL, Warner NL. Cell cycle related heterogeneity of Ia antigen expression on a murine B lymphoma cell line: analysis by flow cytometry. J Immunol 1981; 126: 626-631.
36. Kearney JF, Radbruch A, Liesegang B, et al. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979; 123: 1548-1550.
37. Urlinger S, Baron U, Thellmann M, et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968.
38. Anastassiadis K, Kim J, Daigle N, et al. A predictable ligand regulated expression strategy for stably integrated transgenes in mammalian cells in culture. Gene 2002; 298: 159-172.
39. Qu Z, Thottassery JV, Van Ginkel S, et al. Homogeneity and long-term stability of tetracycline-regulated gene expression with low basal activity by using the rtTA2S-M2 transactivator and insulator-flanked reporter vectors. Gene 2004; 327: 61-73.
40. Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor á chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001; 86: 1261-1269.
41. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002; 100: 2980-2988.
42. Alexander RL, Kucera GL, Klein B, et al. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem 2000; 11: 564-568.
43. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30: 607-613.
44. Alexander RL, Ramage J, Kucera GL, et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001; 25: 875-881.
45. Matsuo Y, MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLLAF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 1997; 11: 1469-1477.
46. Srinivasula SM, Ahmad M, MacFarlane M, et al. Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits. J Biol Chem 1998; 273: 10107-10111.
47. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98: 8662-8667.
48. Krueger C, Berens C, Schmidt A, et al. Single-chain Tet transregulators. Nucleic Acids Res 2003; 31: 3050-3056.
49. Griffiths RA, Boyne JR, Whitehouse A. Herpesvirus saimiri-based gene delivery vectors. Curr Gene Ther 2006; 6: 1-15.
50. Rasko JE, Klenova EM, Leon J, et al. Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res 2001; 61: 6002-6007.
51. Ausserlechner MJ, Obexer P, Deutschmann A, et al. A retroviral expression system based on tetracycline-regulated tricistronic transactivator/repressor vectors for functional analyses of antiproliferative and toxic genes. Mol Cancer Ther 2006; 5: 1927-34.
52. Feuring-Buske M, Frankel AE, Alexander RL, et al. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002; 62: 1730-1736. (Pubitemid 34408495)
53. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.